Myelodysplastic syndrome following chimeric antigen receptor T-cell therapy treated with allogenic stem cell transplantation.
Immunotherapy
; 15(6): 401-407, 2023 04.
Article
in En
| MEDLINE
| ID: mdl-36950962
Chimeric antigen receptor (CAR) T cell is a new type of immunotherapy that was recently validated for the treatment of some types of B-cell lymphoma and leukemia. One of the most recently reported side effects of CAR T cells is the appearance of anemia, thrombocytopenia and/or neutropenia lasting for a long duration. The authors report the case of a patient treated with CAR T cells for non-Hodgkin lymphoma who developed prolonged hematological toxicity. During follow-up, the diagnosis of myelodysplastic syndrome was made and the patient underwent allogenic bone marrow transplantation and remains in complete remission at last follow-up.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Myelodysplastic Syndromes
/
Lymphoma, Large B-Cell, Diffuse
/
Hematopoietic Stem Cell Transplantation
/
Receptors, Chimeric Antigen
Limits:
Humans
Language:
En
Journal:
Immunotherapy
Journal subject:
ALERGIA E IMUNOLOGIA
/
TERAPEUTICA
Year:
2023
Document type:
Article
Affiliation country:
Francia
Country of publication:
Reino Unido